Kiora Pharmaceuticals Reports Additional Clinical Data for K

Kiora Pharmaceuticals, Inc. , announced additional data from ABACUS-1, the Phase I/II clinical trial in patients with retinitis pigmentosa showing KIO-301 significantly increased brain activity,...

Related Keywords

United States , Robert James Casson , Eric Daniels , Nasdaq , Twitter , University Of Adelaide , Kiora Pharmaceuticals , Association For Research , Kiora Pharmaceuticals Inc , Head Of The Ophthalmic Research Lab , Linkedin , California Newsfile Corp , Professor Robert James Casson , Ophthalmic Research Lab , Chief Development Officer , Open Innovation , Private Securities Litigation Reform Act , Annual Report , Markets ,